Perspective Therapeutics, Inc. (CATX) is a clinical-stage biopharmaceutical company focused on targeted alpha therapy (TAT) for cancer treatment. Its pipeline includes VMT-α-NET and VMT01 product candidates, which have received Fast Track designation from the FDA. The company also develops PSV359, a novel asset under an IND application. Perspective operates manufacturing subsidiaries Viewpoint Molecular Targeting, Inc. and Isoray Medical, Inc., and is building a regional network of drug product finishing facilities.
Q2 FY2026 — expected 2026-09-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-16 | 2025-12-31 | 0000728387-26-000004 | EDGAR | 92K words |
| 2025-03-26 | 2024-12-31 | 0000950170-25-045242 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0001437749-24-009696 | EDGAR | — |
| 2022-09-28 | 2022-06-30 | 0001437749-22-023188 | EDGAR | — |
| 2021-09-27 | 2021-06-30 | 0001437749-21-022693 | EDGAR | — |
| 2020-09-25 | 2020-06-30 | 0001437749-20-020189 | EDGAR | — |
| 2019-09-27 | 2019-06-30 | 0001437749-19-019176 | EDGAR | — |
| 2018-09-26 | 2018-06-30 | 0001437749-18-017492 | EDGAR | — |
| 2017-09-28 | 2017-06-30 | 0001144204-17-050344 | EDGAR | — |
| 2016-09-09 | 2016-06-30 | 0001144204-16-123313 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0001193125-25-274328 | EDGAR | 25K words |
| 2025-08-13 | 2025-06-30 | 0000950170-25-107619 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0000950170-25-069314 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125399 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096148 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0000950170-24-060427 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001437749-23-032036 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0001437749-23-023340 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001437749-23-014658 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001437749-22-027304 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001437749-22-012202 | EDGAR | — |
| 2022-02-09 | 2021-12-31 | 0001437749-22-002803 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-01 | 0001193125-26-137930 | EDGAR | 1K words |
| 2026-03-16 | 0000728387-26-000003 | EDGAR | — |
| 2026-02-03 | 0001193125-26-035508 | EDGAR | — |
| 2026-02-02 | 0001193125-26-032706 | EDGAR | — |
| 2026-01-14 | 0001193125-26-012259 | EDGAR | — |
| 2026-01-12 | 0001193125-26-009846 | EDGAR | — |
| 2026-01-09 | 0001193125-26-008277 | EDGAR | — |
| 2025-12-01 | 0001193125-25-303895 | EDGAR | — |
| 2025-11-10 | 0001193125-25-274318 | EDGAR | — |
| 2025-11-06 | 0001193125-25-268124 | EDGAR | — |
464 total filings indexed. 432 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000728387 |
| Ticker | CATX |
| Exchange | NYSE |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.perspectivetherapeutics.com |
| Listed | 2003-12-29 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report